Food & Drug Administration (FDA) has approved certain GLP-1 drugs for commercialization and use, including liraglutide (Victoza), semaglutide (Ozempic, Wegovy), and tirzepatide (Mounjaro, Zepbound)
Additionally, the use of Continuous Glucose Monitoring (CGM) data is discussed as a valuable tool for reducing fluctuations in blood sugar levels and preventing exercise-induced hypoglycemia
It is a water-soluble electron donor [51], and several epidemiological studies have demonstrated that a diet rich in fruits and vegetables is associated with a lower risk of cardiovascular disease CVD, stroke, cancer, and increased life expectancy
Easiest to work with
Liraglutide Liraglutide is a daily injectable GLP-1 receptor agonist available in different doses for different indications
The 4 to 6 hour half-life of BPC-157 means single daily doses create peaks and troughs, while split dosing smooths out this variation